BLA 125516 · United Therap
Unituxin
Dinutuximab · Intravenous · Glycolipid Disialoganglioside-directed Antibody
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Mar 10, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
47
10 Phase 3, 15 recruiting
FAERS reports
859
757 serious, 173 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFUSION REACTIONS AND NEUROTOXICITY WARNING: SERIOUS INFUSION REACTIONS AND NEUROTOXICITY See full prescribing information for complete boxed warning. Infusion Reactions: Life-threatening infusion adverse reactions occur with Unituxin. Administer required prehydration and premedication. Immediately interrupt for severe infusion reactions and permanently discontinue for anaphylaxis [see Dosage and Administration (2.2 , 2.3) and Warnings and Precautions (5.1) ] . Neurotoxicity: Unituxin causes severe neuropathic pain. Administer intravenous opioid prior to, during, and for 2 hours following completion of the Unituxin infusion. Severe peripheral sensory neuropathy ranged from 2% to 9% in patients with neuroblastoma. Severe peripheral motor neuropathy has also been reported. Discontinue for severe unresponsive pain, severe sensory neuropathy, and moderate to severe...
What it is approved for
From the label in effect Jul 6, 2026.
Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ] . Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. ( 1 )
Mechanism: Dinutuximab binds to the glycolipid GD2. This glycolipid is expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. Dinutuximab binds to cell surface GD2 and induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 10, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
- UNITUXIN · DINUTUXIMAB 17.5MG/5ML · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dinutuximab" as an intervention, any sponsor and status, largest first.
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Pivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT04221035 · 800 participants (planned) · Start Nov 5, 2019 · Primary completion Nov 2026
Drug: Vincristine; Carboplatin and 13 more · For: High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy
Sites: Sydney, Australia; Clayton, Australia; Nedlands, Australia · 142 sites in all
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerPivotal-lookingCompleted
United TherapeuticsIndustry
NCT03098030 · 483 participants · Start Jun 1, 2017 · Primary completion Jan 27, 2020
Drug: Dinutuximab; Irinotecan and 1 more · For: Small Cell Lung Cancer
Sites: Anchorage, Alaska; Goodyear, Arizona; Tucson, Arizona · 226 sites in all
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06172296 · 478 participants (planned) · Start Apr 19, 2024 · Primary completion Dec 31, 2029
Drug: Carboplatin; Cisplatin and 11 more · For: Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 180 sites in all
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenPivotal-lookingCompleted
University of BirminghamAcademic, hospital or other
NCT02308527 · 225 participants · Start Jul 2013 · Primary completion Aug 1, 2021
Drug: Bevacizumab; Temozolomide and 7 more · For: Neuroblastoma
Sites: Vienna, Austria; Ghent, Belgium; Copenhagen, Denmark · 10 sites in all
- Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With NeuroblastomaPivotal-lookingStatus unknown
University of LeicesterAcademic, hospital or other
NCT00030719 · 175 participants (planned) · Start Dec 2001
Drug: filgrastim; monoclonal antibody Ch14.18 and 7 more · For: Neuroblastoma
Sites: Vienna, Austria; Ghent, Belgium; Aarhus, Denmark · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia172
- off label use116
- pain90
- neuroblastoma recurrent89
- abdominal pain80
- vomiting68
- aspartate aminotransferase increased64
- alanine aminotransferase increased62
- hypotension59
- anaemia58
- neuroblastoma56
- hypoalbuminaemia55
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 10 |
| 2016 | 24 |
| 2017 | 62 |
| 2018 | 82 |
| 2019 | 62 |
| 2020 | 72 |
| 2021 | 138 |
| 2022 | 106 |
| 2023 | 102 |
| 2024 | 68 |
| 2025 | 61 |
| 2026 | 72 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL, Gilman AL, Ozkaynak MF, et al. · Clin Cancer Res 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, et al. · J Clin Oncol 2020 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Comparative Study
- Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, et al. · Lancet Oncol 2017 · Clinical Trial, Phase II, Multicenter Study
- Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt T, Ladenstein RL, Ebinger M, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: United Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.